First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson’s disease expected in H1 2025 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 ...

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company. On ...

Group 1 - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel oral therapies for inflammatory diseases with significant unmet medical needs [2] - The company has a pipeline that includes clinical programs targeting NLRP3, S1P1R, and TYK2, aiming to lead in oral immunology therapies for peripheral and neuroinflammatory diseases [2] - Ventyx will participate in several upcoming investor conferences, including the Stifel 2024 Healthcare Conference, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference [1] Group 2 - The Stifel 2024 Healthcare Conference will take place on November 18, 2024, in New York, NY, from 4:10-4:40 PM ET [1] - The Jefferies London Healthcare Conference is scheduled for November 20, 2024, in London, UK, from 8:00-8:25 AM GMT [1] - The Piper Sandler Healthcare Conference will occur on December 4, 2024, in New York, NY, from 4:00-4:25 PM ET [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ | --- | --- | |-----------------------------------------------------------------------------------------------|-------------------------- ...

Exhibit 99.1 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson's disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results ...

Shares of Ventyx Biosciences (VTYX) gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi (SNY) . Per the terms of the deal, Sanofi will buy 70,601 of Ventyx's Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock. The proceeds from this investment are anticipated to enhance Ventyx's cash reserves. With t ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease. "We are excited to initiate this trial of VTX3232 in patients with early Parkinson's disease," said Mark Forman ...

SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: 2024 Wells Fargo Healthcare Conference Location: Boston, MA Date: Wednesday, September 4, 2024 Time: 11:00-11:35 AM ET ...

A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024 A Phase 2 trial of VTX2735 in recurrent pericarditis is expected to initiate in H2 2024 Mark Forman, MD, PhD will join Ventyx as Chief Medical Officer effective August 12, 2024 Cash, cash equivalents and marketable securities of $279.7 million as of June 30, 2024 are expected to fund planned operations into at least the second half of 2026 SAN D ...